TEM changes
Pick any two versions below to diff them.
- Price
- $54.04
- Discount category
- Close to intrinsic value
- Intrinsic value source
- AI estimate
- Next earnings
- Feb 2, 2027
- Next earnings is estimate
- Yes
- Company name
- added: Tempus AI
- Sector
- added: AI diagnostics and health data
- About
- added: Tempus AI, Inc. (TEM) is based in Chicago, Illinois. It uses AI and a large library of de-identified clinical and molecular data for precision medicine. Its Diagnostics business runs genomic tests for cancer, such as tumor profiling and minimal residual disease (MRD) tests, and hereditary tests. Its Data and Applications business licenses data and AI models to pharmaceutical companies and sells AI tools for doctors, such as algorithms for the ECG with FDA clearance. In 2025, revenue was $1,271.8 million: Diagnostics gave $955.4 million and Data and Applications $316.4 million. The Class A common stock trades on Nasdaq in US dollars, and each Class B share converts into one Class A share. Tempus files 10-K and 10-Q reports.
- Thesis
- added: The price of Tempus AI depends on how fast its test volumes and data licenses grow and on when it earns a GAAP profit. In Q3 2026, revenue grew 23%, oncology volume grew 32%, Data and Applications revenue grew 33% and adjusted EBITDA was $25.6 million. Investors pay a high multiple of revenue because they see Tempus as an AI and data company, and the AI estimate gives less value because most revenue still comes from tests that payers reimburse, net losses continue and stock-based compensation is large. For the AI estimate to rise toward the price, three things must be true. Revenue must grow by about 20% or more a year after 2026, from the 2026 guidance of $1.60 billion to $1.605 billion. Adjusted EBITDA must grow well above the guided $65 million for 2026, and GAAP losses must end. Data licensing bookings, more than $550 million so far in 2026, must turn into revenue. The vote of Personalis stockholders on November 30, 2026, the Q4 2026 report, expected in early February 2027, and results through 2027 are the next tests.
- Valuation
- added: The intrinsic value for Tempus AI is an AI estimate from November 14, 2026. It is not an analyst's value. An AI research agent calculated it from the filings of Tempus AI with the SEC. The pick is the Class A common stock on Nasdaq. Each Class B share converts into one Class A share, so the estimate counts both classes as one. The method is a multiple of 2027 revenue, less net debt, divided by the shares and unvested equity awards. The Q4 2025 release (8-K, February 24, 2026) gives 2025 revenue of $1,271.8 million and an adjusted EBITDA loss of $7.4 million. The Q3 2026 release (8-K, November 2, 2026) gives Q3 revenue of $411.5 million, up 23%, adjusted EBITDA of $25.6 million, a net loss of $14.9 million, and cash and marketable securities of $854.4 million. It raises 2026 revenue guidance to $1.60 billion to $1.605 billion and expects adjusted EBITDA of about $65 million. The Form 10-Q for the quarter ended September 30, 2026 gives $750.0 million of 0.75% convertible senior notes due 2030, $460.0 million of 0.00% convertible senior notes due 2032 and a convertible promissory note carried at $176.0 million, so net debt is $531.6 million. The estimate counts the notes as debt at their principal and leaves out the capped calls, which is an assumption. The cover of the 10-Q gives 177,357,848 Class A shares and 5,043,789 Class B shares at October 29, 2026, and the 10-Q gives 5,931,276 unvested restricted stock units, 7,601 restricted stock awards and 1,929,552 performance stock units at September 30, 2026. The estimate thus uses 190.27 million shares. Stock-based compensation was $154.9 million in nine months, and the estimate counts it through the units and the multiples, which is an assumption. The pending purchase of Personalis for $16.25 per share, mostly in Class A shares, is left out, and the estimate assumes that it neither adds nor removes value per share, which is an assumption. The 2027 revenue and the multiples are assumptions. The low case assumes $1,840 million, because test volumes and data licenses grow more slowly, at 3.5 times revenue. It gives $31.05 per share. The base case assumes $1,960 million, or growth of about 22%, at 5.5 times. It gives $53.86 per share. The high case assumes $2,080 million, from fast growth in MRD tests and data licensing, at 8 times. It gives $84.66 per share. The estimate assumes weights of 25%, 50% and 25%. The weighted intrinsic value is $55.86 per share. Tempus has a large library of clinical and molecular data and links with many oncologists, which helps its data licensing, but many laboratories sell similar genomic tests, and payers set much of the price. As of Nov 14, 2026.
- Risks
- added: Most Diagnostics revenue depends on payment from Medicare, Medicaid and commercial insurers. At December 31, 2025, Tempus had received payment on about 55% of its clinical oncology tests. Lower prices or less coverage can cut revenue. Tempus still has net losses, and stock-based compensation was $154.9 million in the first nine months of 2026. The convertible notes and equity awards can add about 23.4 million shares. The purchase of Personalis is paid mostly in shares and can still fail. The integration of Personalis and of earlier purchases, such as Ambry Genetics and Paige, can cost more than planned. Data licensing depends on large multi-year agreements with a few pharmaceutical companies, such as AstraZeneca and Pathos, and a contract can end or be delayed. Many laboratories sell similar genomic and MRD tests, and new rules from the FDA for laboratory tests can raise costs.
- Balance sheet
- added: Cash: $854M Debt: $1.4B Net debt: $532M Last debt due: 2032 At September 30, 2026, Tempus had cash and marketable securities of $854.4 million, of which cash and cash equivalents were $590.5 million. Debt was $750.0 million of 0.75% Convertible Senior Notes due 2030, with a conversion price of about $84.19, $460.0 million of 0.00% Convertible Senior Notes due 2032, with a conversion price of about $69.26, and a convertible promissory note carried at $176.0 million. Capped calls reduce the dilution from the notes. In 2026, Tempus repaid its long-term debt of $202.8 million and its revolving credit facility of $100.0 million. As of Sep 30, 2026.
- Checkpoints
- added: Nov 30, 2026: Personalis stockholder vote. Pending. Watch: Personalis stockholders approve the merger and the deal closes in Q4 2026, and this passes; a failed vote or an end of the agreement fails. Feb 2, 2027 (estimate): Q4 2026 results. Pending. Watch: 2026 revenue is in the guided range of $1.60 billion to $1.605 billion, adjusted EBITDA is about $65 million or more, and the 2027 outlook gives growth of about 20% or more, and this passes; lower growth or a weaker outlook fails.
- Recent events
- added: Nov 2, 2026: Tempus reported Q3 2026 results. Revenue rose 23% to $411.5 million, Diagnostics revenue rose 20% and Data and Applications revenue rose 33%. The net loss was $14.9 million and adjusted EBITDA was $25.6 million. It raised its 2026 revenue guidance to $1.60 billion to $1.605 billion. It also said that a collaboration with BMS in October brought its data licensing bookings to more than $550 million in 2026. Jul 30, 2026: Tempus reported Q2 2026 results. Revenue rose 22% to $382.5 million, GAAP net income was $5.6 million and adjusted EBITDA was $8.0 million. The FDA approved its xT Tumor Only test. Jul 20, 2026: Tempus agreed to buy the shares of Personalis that it does not already own for $16.25 per share, mostly in Class A shares, an enterprise value of $1.5 billion. Personalis can end the agreement if the average price of Tempus shares before the closing is below $46.00. May 12, 2026: Tempus sold $460.0 million of 0.00% Convertible Senior Notes due 2032, with a conversion price of about $69.26, for net proceeds of $442.0 million. May 5, 2026: Tempus reported Q1 2026 results with revenue of $348.1 million and a net loss of $125.9 million. Feb 24, 2026: Tempus reported 2025 results. Revenue rose 83.4% to $1,271.8 million, the net loss was $245.0 million and the adjusted EBITDA loss was $7.4 million. It guided 2026 revenue of $1.59 billion and adjusted EBITDA of about $65 million.